T1	intervention 0 43	Abemaciclib Combined With Endocrine Therapy
T2	eligibility 818 947	patients with HR+, HER2-, high-risk EBC, who had surgery and, as indicated, radiotherapy and/or adjuvant/neoadjuvant chemotherapy
T3	control 1133 1149	standard-of-care
T4	outcome-Measure 1270 1308	invasive disease-free survival (IDFS),
T6	total-participants 1453 1458	5,637
T7	outcome 1491 1502	IDFS events
T8	outcome 1594 1598	IDFS
T9	outcome 1673 1690	2-year IDFS rates
T10	iv-bin-percent 1694 1699	92.2%
T11	cv-bin-percent 1707 1712	88.7%
T5	outcome-Measure 1343 1372	distant relapse-free survival
T12	outcome-Measure 1374 1390	overall survival
T13	outcome-Measure 1396 1402	safety
